March 3 (Reuters) - Traws Pharma TRAW.O:
TRAWS PHARMA: REPORTS POSITIVE RESULTS FROM ACCEPTED BIRD FLU MODEL FOR ANTI-VIRAL CANDIDATE, TIVOXAVIR MARBOXIL
TRAWS PHARMA: TOPLINE DATA FROM FERRET MODEL TESTING SHOW THAT TIVOXAVIR MARBOXIL HAS POTENTIAL TO INHIBIT DISEASE AFTER BIRD FLU INFECTION
TRAWS PHARMA: CONDUCTING SIMILAR CHALLENGE STUDY IN NON-HUMAN PRIMATES, WITH DATA EXPECTED IN Q1 2025
Source text: [ID:]
Further company coverage: TRAW.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.